证券代码：688108 证券简称：赛诺医疗 公告编号：2024-059 赛诺医疗科学技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次申请授信额度的基本情况 二、对公司的影响 公司本次向金融机构申请的综合授信额度总金额：1.2 亿元 使用期限：本次综合授信额度自董事会决议生效之日起有效期 2 年，有效期内可 多次审批，授信额度可循环使用。 关于向金融机构申请授信额度的公告 为满足赛诺医疗科学技术股份有限公司（以下简称"公司"或"赛诺医疗"）业 务发展及经营需要，进一步拓宽融资渠道，优化公司资本结构，公司于2024年10月29 日召开第三届董事会第四次会议、第三届监事会第四次会议，分别审议通过《赛诺医 疗科学技术股份有限公司关于向中国农业银行股份有限公司天津经济技术开发区分 行申请授信额度的议案》。公司拟向中国农业银行股份有限公司天津经济技术开发区 分行申请总计不超过人民币1.2亿元的综合授信额度，用于办理包括但不限于人民币 /外币贷款，开具银行承兑汇票、信用证、保函，汇票贴现等在内 ...

舆情管理办法 赛诺医疗科学技术股份有限公司 第一章 总则 第一条 为提高赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）应 对各类网络舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类网络舆情对公 司品牌形象、商业信誉、股价及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据《上海证券交易所科创板股票上市规则》等相关法律法规、规范性文件及《赛诺医疗科 学技术股份有限公司章程》的相关规定，并结合公司实际情况，制定本办法。 第二条 本办法所称网络舆情包括但不限于下列内容： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或将会给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影响的事 件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动，使公司已 经或可能遭受损失，已经或可能造成公司股票及衍生品种交易价格异常变动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-057 赛诺医疗科学技术股份有限公司 关于第三届董事会第四次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届董 事会第四次会议通知于 2024 年 10 月 23 日以书面方式送达各位董事和监事。会议于 2024 年 10 月 29 日以现场和通讯相结合的方式在公司会议室召开。本次会议应出席董 事 9 人，实际出席董事 9 人。本次会议由董事长孙箭华先生召集并主持，公司监事、 高管列席了本次会议。本次会议的召开符合《中华人民共和国公司法》等有关法律、 法规、规范性文件及赛诺医疗《赛诺医疗科学技术股份有限公司章程》《赛诺医疗科 学技术股份有限公司董事会议事规则》等的规定，会议召开程序合法有效。 二、董事会会议审议情况 经与会董事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2024 年第三季度报告的议案" 经与会董事审议， ...

Revenue and Sales Performance - Revenue for the third quarter was RMB 104.79 million, a 25.76% increase year-over-year[3] - Year-to-date revenue reached RMB 318.49 million, up 30.20% compared to the same period last year[3] - The increase in revenue was primarily driven by a significant growth in sales of coronary products[7] - Total operating revenue for the first three quarters of 2024 reached 318,486,443.24 RMB, a significant increase from 244,617,074.10 RMB in the same period of 2023[16] - Sales revenue from goods and services reached 358,433,488.89 RMB, a notable increase from the previous year[20] Net Profit and Loss - Net loss attributable to shareholders for the third quarter was RMB -14.41 million[3] - Year-to-date net loss attributable to shareholders was RMB -6.74 million[3] - Net profit attributable to the parent company's shareholders was -241,473,911.19 RMB in Q3 2024, slightly worse than -234,729,458.31 RMB in 2023[15] - Net profit attributable to parent company shareholders was -6,744,452.88 RMB, a significant loss compared to the previous year[18] - Total comprehensive income was -6,900,442.91 RMB, indicating a substantial decline in overall financial performance[18] - Basic earnings per share were -0.02 RMB, indicating a loss per share[18] R&D Investment and Expenses - R&D investment for the third quarter was RMB 59.72 million, a 58.46% increase year-over-year[3] - Year-to-date R&D investment totaled RMB 151.95 million, up 28.67% compared to the same period last year[3] - R&D expenses increased to 106,407,498.18 RMB in the first three quarters of 2024, up from 80,498,702.34 RMB in 2023[16] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 1.28 billion, a 7.95% increase from the end of the previous year[4] - Equity attributable to shareholders was RMB 857.51 million, a 4.58% increase from the end of the previous year[4] - Total assets as of Q3 2024 stood at 1,280,072,535.51 RMB, up from 1,185,821,379.98 RMB in the previous year[13][15] - Total liabilities for Q3 2024 were 381,222,588.88 RMB, compared to 324,171,588.85 RMB in 2023[14][15] - Long-term liabilities increased to 224,481,917.36 RMB in Q3 2024, compared to 172,899,093.28 RMB in 2023[14] - Development expenditure rose to 377,364,683.16 RMB in Q3 2024, up from 331,823,588.24 RMB in 2023[13] - Inventory levels slightly increased to 120,649,871.70 RMB in Q3 2024 from 118,220,173.59 RMB in the previous year[13] Cash Flow and Liquidity - Operating cash flow for the year-to-date period was RMB 49.72 million, a 37.18% increase year-over-year[3] - Cash flow from operating activities increased to 49,720,487.28 RMB, showing improved operational efficiency[20] - Cash flow from investing activities was -72,000,968.51 RMB, reflecting significant investment outflows[21] - Cash flow from financing activities was 59,422,575.01 RMB, indicating strong external funding support[21] - Total cash and cash equivalents at the end of the period were 224,939,661.92 RMB, showing a healthy liquidity position[21] - Total cash inflow from financing activities was 121,906,687.94 RMB, highlighting robust fundraising efforts[21] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 10,402[9] - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, representing 17.38% of total shares[9] - Guo Yanchao holds 22,770,854 shares, representing 5.51% of total shares[9] - China Bank - Guotai Jiangyuan Advantage Selection Flexible Allocation Mixed Securities Investment Fund holds 12,295,278 shares, representing 2.97% of total shares[9] - Tianjin Sunshine Guangye Enterprise Management Partnership holds 10,628,155 shares, representing 2.57% of total shares[9] - Huang Songlang holds 10,000,000 shares, representing 2.42% of total shares[9] - Tianjin Sunshine Deye Enterprise Management Partnership holds 8,208,381 shares, representing 1.99% of total shares[9] - Li Guangxin holds 7,852,056 shares, representing 1.90% of total shares[9] - China Bank - Guotai Zhiyuan Advantage Mixed Securities Investment Fund holds 7,642,073 shares, representing 1.85% of total shares[9] - China Construction Bank - Guotai Pharmaceutical Health Equity Securities Investment Fund holds 7,246,706 shares, representing 1.75% of total shares[10] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 amounted to 355,578,619.17 RMB, compared to 301,656,954.40 RMB in 2023[16] - Total assets impairment loss was -7,904,949.40 RMB, reflecting significant write-downs[18]

Company Updates - The company's subsidiary, Sinomed Shenchang, showcased its innovative products, including the self-expanding intracranial drug-coated stent and the flow-diverter coated mesh stent, at the OCIN 2024 conference [1] - The company's self-developed COMETIU stent, the world's first self-expanding intracranial drug-coated stent, passed the NMPA's innovative medical device approval in April 2024 and was submitted for domestic medical device registration in May 2024 [1] - The COMETIU stent demonstrated a post-operative 6-month in-stent restenosis (ISR) rate of 1.72% and a stroke or death rate of 3.13% in clinical trials [1] - The company's flow-diverter coated mesh stent, another innovative product, showed promising results in a single-center clinical trial at Wuhan Union Hospital, with 27 patients and 29 aneurysms included in the study [1] - The flow-diverter coated mesh stent achieved a Raymond I rate of 88.46% and a Raymond I+II rate of 87.88% at 6 months, and a Raymond I+II rate of 92.41% at 1 year, with no post-operative stroke events reported [2] - The company's flow-diverter coated mesh stent is the first in China to be delivered via a 017 system, featuring a new alloy material, proprietary electronic coating grafting technology, and the smallest delivery profile globally [2] - The company's neurovascular business is entering a harvest period with the upcoming market entry of its innovative products, including the flow-diverter coated mesh stent [3] Industry Insights - Intracranial atherosclerotic stenosis (ICAS) is a common cause of ischemic stroke, particularly in Asian populations, with higher recurrence rates as stenosis severity increases [1] - Intracranial stent placement has become a highly anticipated treatment for ICAS, with the COMETIU stent significantly reducing post-operative restenosis rates and stroke or death rates [1] - The company's product pipeline, including the NOVA intracranial drug-eluting stent approved in 2021 and the intracranial thrombectomy stent approved in the first half of 2023, positions it to meet diverse stent needs for ischemic stroke intervention [2]

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-055 赛诺医疗科学技术股份有限公司关于 公司冠脉产品在摩洛哥获得注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2024 年向 摩洛哥药物和药品部门(以下简称"DMP")递交了公司 SC HONKYTONKTM 冠脉球囊扩张导 管的注册申报资料。公司于近日收到通知，公司 SC HONKYTONKTM 冠脉球囊扩张导管的注 册申报资料获得 DMP 的批准。现将相关情况公告如下： 二、医疗器械基本情况 本次获得 DMP 注册证的 SC HONKYTONKTM 冠脉球囊扩张导管，可用于狭窄病变的扩张， 也可用作 PCI 支架植入前的预扩张。极小的导入外径使产品与导丝更贴合；柔软的球囊 材料和三翼折叠技术使产品具有良好的柔顺性和再通过性；较小的外管外径，提高球囊 对吻性能，可实现全规格对吻。该产品已于 2022 年 12 月 14 日获得中国国家药品监督管 理局 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage in the market [3][7]. Core Views - The company has been deeply engaged in the vascular intervention field for over a decade, with innovative products expected to yield significant returns. The dual-track approach in neurointervention and cardiovascular business is forming a solid growth foundation [3]. - The penetration rate for stroke intervention treatments is currently low, with multiple innovative products in development to create a comprehensive neurointervention product matrix. The domestic neurointervention market is projected to grow significantly, reaching 176 billion yuan by 2026, with a compound annual growth rate of 20.1% from 2020 to 2026 [3][30]. - The company has successfully participated in centralized procurement for coronary stents, leading to a substantial recovery in its coronary business, with a revenue increase of 99.1% year-on-year in 2023 [3][9]. Summary by Sections Company Overview - Founded in 2007, the company focuses on high-value interventional medical devices, with a product portfolio that includes drug-eluting stents and balloon catheters. It has established a presence in over 3,000 hospitals [16][17]. Financial Projections - Revenue forecasts for 2024-2026 are 480 million, 707 million, and 941 million yuan, respectively, with year-on-year growth rates of 39.95%, 47.20%, and 33.08% [4][7]. - The net profit attributable to shareholders is projected to be 3.21 million, 47.52 million, and 105.97 million yuan for the same period, with growth rates of 108.11%, 1379.33%, and 122.99% [4][6]. Market Dynamics - The report highlights the low penetration of neurointervention treatments and the increasing demand for innovative products in this area. The company is actively involved in clinical trials and regulatory approvals globally, aiming to establish itself as a leading brand in innovative medical devices [3][30]. - The coronary stent business has shown a significant recovery due to successful bids in centralized procurement, with a marked increase in sales volume and revenue [3][9]. Product Development - The company has a robust pipeline of innovative products, including self-expanding intracranial drug-eluting stents and coated stents, which are at various stages of clinical trials and approvals [3][30]. - The report emphasizes the importance of continuous R&D investment, with a focus on developing core technologies that enhance product efficacy and market competitiveness [26][28].

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-054 赛诺医疗科学技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、股票交易异常波动的具体情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）股票交易于 2024 年 9 月 30 日、2024 年 10 月 8 日、2024 年 10 月 9 日连续 3 个交易日内日收盘价 格跌幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创 板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 1、经自查，公司目前日常生产经营情况正常，市场环境、行业政策等均未发生重 大调整。敬请广大投资者注意投资风险。 2、经书面问询公司控股股东天津伟信阳光企业管理咨询有限公司、实际控制人孙 箭华先生及其一致行动人天津阳光广业企业管理合伙企业（有限合伙）、天津阳光德业 企业管理合伙企业（有限合伙）、天津阳光永业企业管理合伙企业（有限合伙 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2024-053 赛诺医疗科学技术股份有限公司 关于子公司产品获得国内医疗器械注册证的公告 结构及组成: 该产品由管体、显影标记、球囊、应力释放管和接头组成。附件包含 导引鞘、无针接头、延长管、MPA 扩张管、VTK 扩张管。产品经环氧乙烷灭菌，一次性使 用，货架有效期 3 年。 适用范围：该产品预期用于协助血管内导管插入并被引导至外周或神经血管系统的 目标血管内。在进行血管造影时，球囊可提供临时性的血管阻塞作用。该产品还可以用 于为治疗和介入器械建立通路。 有效期至：2029 年 9 月 29 日 二、医疗器械基本情况 本次获得《医疗器械注册证》的球囊导引导管，是由公司控股子公司赛诺神畅自主 研发并进行生产的一款导管产品。球囊导引导管配备 MPA、VTK 扩张管，利于超选复杂弓 型血管，辅助球囊导引导管高效到位，完善的配件组合，手术操作更便捷。大内腔设计， 优化管腔兼容性和血栓捕捉能力。多个推送节段设计，提供近端良好的支撑力和远端的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承 ...

Group 1: Financial Performance - In the first half of 2024, the company achieved operating revenue of 214 million yuan, representing a year-on-year growth of 32.49% [2] - The net profit attributable to shareholders of the listed company was -1,259.33 million yuan, with a significant increase of 125.88% [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 766.20 million yuan, reflecting a year-on-year growth of 64% [2] Group 2: Investor Relations Activity - The investor relations activity took place on September 19, 2024, from 14:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [2] - Key personnel present included Shen Lihua (Director, CFO), Huang Kai (Director, Board Secretary), and Ma Yuan (Independent Director) [2] - The activity was categorized as a performance briefing for the first half of 2024 [2]